Wall Street rewarded a story of volume. It punished a story of prices. Alphatec Holdings gave investors both narratives last week, and the market’s reaction was a sharp lesson in short-term priorities. The medical device maker posted third-quarter results that highlighted a powerful, fundamental growth engine. Its surgical volumes jumped roughly 20% year-over-year. It attracted about 25% more new surgeons to its platform. This is the kind of metric that makes analysts nod. It speaks to a company gaining real traction with its core customers. Yet the stock moved lower after the report. The reason lies in the other narrative, the one about the value of each procedure. Alphatec’s revenue per case dropped by 5%. This decline pulled total revenue of $221 million below expectations. It also forced management to cut its full-year sales forecast.
The details of the call, which I reviewed, reveal a classic business struggle. It is the push and pull between expanding your customer base and defending your profit per customer. Alphatec is clearly winning at expansion. CEO Pat Miles noted the company is adding surgeons at a record pace. Its surgical hardware revenue grew 17%. This indicates that once surgeons come onboard, they are using more Alphatec equipment. This is a sign of a healthy ecosystem. The problem is happening at the point of sale for each surgery. Specifically, it involves a product category called biologics. These are substances used to promote bone healing. They are a standard part of many spinal procedures. For Alphatec, they have become a point of vulnerability.
Miles explained the issue with blunt clarity. Biologics are often the least distinctive part of a complex spinal surgery kit. This makes them a target. Smaller competitors, sometimes selling only biologics, are offering them at lower prices. They are willing to accept thinner margins to get a foot in the door with hospitals. Miles admitted this is a sales discipline problem for his own team. “I am profoundly irritated by the lack of discipline,” he said on the call. Hospitals, under budget pressure, are increasingly putting biologics out for separate bids. This creates what Miles called a “hunting license” for these lower-priced rivals. The result is “leakage.” Surgeons might use Alphatec’s hardware but a competitor’s cheaper biologic. That leakage dragged biologics revenue down by $1 million year-over-year last quarter.
This is more than a minor product issue. Historically, biologics have contributed between $15 million and $25 million of annual growth for Alphatec, according to CFO Todd Koning. The forecast now implies that contribution will be flat for the rest of the year. This pressure exposes a financial truth. You can grow your customer count impressively, but if the average spend per customer declines, your overall growth trajectory stalls. The company’s revised full-year revenue guide of about $862 million is roughly $20 million lower than its previous outlook. Koning noted that about $12 million of that shortfall is tied directly to surgical volume, split between lower biologics expectations and softer procedural volumes.
There is a secondary headwind, one that speaks to the broader economic environment. Koning stated the spine market itself has slowed. It was expected to grow at a mid-single-digit pace. Now it feels like a low single-digit growth market. He cited “broader-based softness” in thoracolumbar procedure volumes. This is a reminder that even the best execution can be buffeted by wider industry tides. When patients postpone elective surgeries, or when hospital budgets tighten, even a company with superior products feels the impact. Alphatec’s story is not unfolding in a vacuum.
Yet within these challenges, you find signs of underlying strength. The company’s gross margin expanded by nearly two full percentage points to 72%. This is a critical metric. It shows that Alphatec is managing its core manufacturing and supply chain costs effectively. Its adjusted EBITDA, a measure of operating profitability, surged 46% to $38 million. The margin on that profit jumped over four percentage points to 17%. This tells you the business model is inherently profitable when running well. The company also generated positive free cash flow for the fifth straight quarter. It used some of that cash to pay off debt. The balance sheet is stronger today than it was last year.
Investors on the call were rightly focused on the future. One pressed the management team on its long-range goal of reaching $1 billion in revenue and $180 million in adjusted EBITDA by 2027. Koning was cautious. He said the company is in the midst of its planning process and would not give specific guidance. He pointed to several bright spots:
- Surgical hardware growth is durable
- The company’s EOS imaging system shows promise
- New technologies like the Valence robotic navigation system are rolling out as planned
- Alphatec is adding surgeons at a record pace
- Gross margin expanded to 72%
- Adjusted EBITDA surged to $38 million
But Koning kept circling back to biologics. He urged caution, given the difficulty in predicting when new sales discipline measures will take full effect. The company expects to have its own unique biologic, a BMP, by around 2029. That could help structurally defend this part of the business. Until then, it is a matter of blocking and tackling. Miles vowed an aggressive “carrot and stick” approach with the sales force. This involves enforcing exclusivity clauses in distributor contracts and holding sales managers directly accountable.
The takeaway for you is about where to look for a company’s resilience. Alphatec’s volume growth proves its core technology is in demand. Its margin expansion proves it can run its factory efficiently. Its balance sheet progress proves it is managing its finances responsibly. These are foundational strengths. The pricing pressure in biologics is a real, near-term go-to-market challenge. It is the type of problem a growing company often encounters as it scales. The market is judging Alphatec on its ability to solve this executional issue. If it can stabilize revenue per case while maintaining its surge in surgeon adoption, the current weakness could prove temporary.
| Metric | Value |
|---|---|
| Surgical Volume Growth | 20% |
| New Surgeons Attracted | 25% |
| Revenue per Case Decline | 5% |
| Total Revenue | $221 million |
| Revised Full-Year Revenue Guide | $862 million |
| Adjusted EBITDA | $38 million |
The numbers to watch next quarter will not just be total revenue. Watch the trend in average case value. That metric will tell you if the discipline Miles promised is taking hold.
